Christoph Rader

Christoph Rader, Ph.D.

Professor

Department: SR-IM-RADER LAB
Business Phone: (561) 228-2053
Business Email: c.rader@ufl.edu

About Christoph Rader

Related Links:
Additional Positions:
Professor
2019 – 2022 · The Scripps Research Institute (Jupiter, FL)
Associate Dean, Skaggs Graduate School of Chemical and Biological Sciences
2018 – 2022 · The Scripps Research Institute (Jupiter, FL)
Associate Professor with Tenure
2012 – 2019 · The Scripps Research Institute (Jupiter, FL)
Senior Scientist
2003 – 2012 · National Cancer Institute, National Institutes of Health (Bethesda, MD)
Assistant Professor
1999 – 2003 · The Scripps Research Institute (La Jolla, CA)
Postdoc
1996 – 1999 · The Scripps Research Institute (La Jolla, CA)

Research Profile

Next-generation antibodies for cancer therapy

Open Researcher and Contributor ID (ORCID)

0000-0001-9955-3454

Areas of Interest
  • Antibodies
  • Biochemistry
  • Cancer Immunology and Immunotherapy
  • Chemical biology

Publications

2022
Functional Characterization of Cytochrome P450 Hydroxylase YpmL in Yangpumicin A Biosynthesis and Its Application for Anthraquinone-Fused Enediyne Structural Diversification.
Organic letters. 24(5):1219-1223 [DOI] 10.1021/acs.orglett.2c00009. [PMID] 35084871.
2022
ROR1 targeted immunoliposomal delivery of OSU-2S shows selective cytotoxicity in t(1;19)(q23;p13) translocated B-cell acute lymphoblastic leukemia.
Leukemia research. 118 [DOI] 10.1016/j.leukres.2022.106872. [PMID] 35640397.
2022
ROR1-targeting switchable CAR-T cells for cancer therapy
Oncogene. 41(34):4104-4114 [DOI] 10.1038/s41388-022-02416-5. [PMID] 35859167.
2022
Sculpting a Uniquely Reactive Cysteine Residue for Site-Specific Antibody Conjugation
Bioconjugate Chemistry. 33(6):1192-1200 [DOI] 10.1021/acs.bioconjchem.2c00146.
2021
A new immunochemical strategy for triple-negative breast cancer therapy.
Scientific reports. 11(1) [DOI] 10.1038/s41598-021-94230-4. [PMID] 34290315.
2021
Adoptive T cell immunotherapy for medullary thyroid carcinoma targeting GDNF family receptor alpha 4.
Molecular therapy oncolytics. 20:387-398 [DOI] 10.1016/j.omto.2021.01.012. [PMID] 33614919.
2021
An Engineered Arginine Residue of Unusual pH-Sensitive Reactivity Facilitates Site-Selective Antibody Conjugation
Biochemistry. 60(14):1080-1087 [DOI] 10.1021/acs.biochem.0c00955. [PMID] 33754696.
2021
Antibody-based cancer therapy
Oncogene. 40(21):3655-3664 [DOI] 10.1038/s41388-021-01811-8. [PMID] 33947958.
2021
BTK inhibitors, irrespective of ITK inhibition, increase efficacy of a CD19/CD3-bispecific antibody in CLL
Blood. 138(19):1843-1854 [DOI] 10.1182/blood.2020009686. [PMID] 34046681.
2021
Challenges and opportunities to develop enediyne natural products as payloads for antibody-drug conjugates
Antibody Therapeutics. 4(1):1-15 [DOI] 10.1093/abt/tbab001. [PMID] 33554043.
2021
Discovery of ammosesters by mining the Streptomyces uncialis DCA2648 genome revealing new insight into ammosamide biosynthesis
Journal of Industrial Microbiology and Biotechnology. 48(3-4) [DOI] 10.1093/jimb/kuab027. [PMID] 33982054.
2021
Immunogenic Chemotherapy Enhances Recruitment of CAR-T Cells to Lung Tumors and Improves Antitumor Efficacy when Combined with Checkpoint Blockade
Cancer Cell. 39(2):193-208.e10 [DOI] 10.1016/j.ccell.2020.11.005. [PMID] 33357452.
2021
Integrated functional and spatial profiling of tumour immune responses induced by immunotherapy: the iPROFILER platform.
Immuno-oncology technology. 10 [DOI] 10.1016/j.iotech.2021.100034. [PMID] 35174321.
2021
Mutations derived from horseshoe bat ACE2 orthologs enhance ACE2-Fc neutralization of SARS-CoV-2
PLOS Pathogens. 17(4) [DOI] 10.1371/journal.ppat.1009501. [PMID] 33836016.
2021
Siglec-6 is a target for chimeric antigen receptor T-cell treatment of chronic lymphocytic leukemia
Leukemia. 35(9):2581-2591 [DOI] 10.1038/s41375-021-01188-3. [PMID] 33633313.
2021
The ROR1 antibody-drug conjugate huXBR1-402-G5-PNU effectively targets ROR1+ leukemia.
Blood advances. 5(16):3152-3162 [DOI] 10.1182/bloodadvances.2020003276. [PMID] 34424320.
2020
Affinity maturation, humanization, and co-crystallization of a rabbit anti-human ROR2 monoclonal antibody for therapeutic applications
Journal of Biological Chemistry. 295(18):5995-6006 [DOI] 10.1074/jbc.ra120.012791.
2020
Bispecific antibodies in cancer immunotherapy
Current Opinion in Biotechnology. 65:9-16 [DOI] 10.1016/j.copbio.2019.11.020. [PMID] 31841859.
2020
Characterization of TnmH as an O-Methyltransferase Revealing Insights into Tiancimycin Biosynthesis and Enabling a Biocatalytic Strategy To Prepare Antibody–Tiancimycin Conjugates
Journal of Medicinal Chemistry. 63(15):8432-8441 [DOI] 10.1021/acs.jmedchem.0c00799. [PMID] 32658465.
2020
Chemically Programmable and Switchable CAR‐T Therapy
Angewandte Chemie. 132(29):12276-12283 [DOI] 10.1002/ange.202005432.
2020
Chemically Programmable and Switchable CAR‐T Therapy
Angewandte Chemie International Edition. 59(29):12178-12185 [DOI] 10.1002/anie.202005432. [PMID] 32329959.
2020
Generation and validation of structurally defined antibody–siRNA conjugates
Nucleic Acids Research. 48(10):5281-5293 [DOI] 10.1093/nar/gkaa286. [PMID] 32347936.
2020
Redirecting cytotoxic T cells with chemically programmed antibodies.
Bioorganic & medicinal chemistry. 28(24) [DOI] 10.1016/j.bmc.2020.115834. [PMID] 33166926.
2020
SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity
Nature Communications. 11(1) [DOI] 10.1038/s41467-020-19808-4. [PMID] 33243994.
2020
Site-Specific Antibody–Drug Conjugates in Triple Variable Domain Fab Format
Biomolecules. 10(5) [DOI] 10.3390/biom10050764. [PMID] 32422893.
2019
An IgG1-like bispecific antibody targeting CD52 and CD20 for the treatment of B-cell malignancies.
Methods (San Diego, Calif.). 154:70-76 [DOI] 10.1016/j.ymeth.2018.08.008. [PMID] 30145356.
2019
Chimeric Antigen Receptor Library Screening Using a Novel NF-κB/NFAT Reporter Cell Platform.
Molecular therapy : the journal of the American Society of Gene Therapy. 27(2):287-299 [DOI] 10.1016/j.ymthe.2018.11.015. [PMID] 30573301.
2019
Conventional and Chemically Programmed Asymmetric Bispecific Antibodies Targeting Folate Receptor 1.
Frontiers in immunology. 10 [DOI] 10.3389/fimmu.2019.01994. [PMID] 31497024.
2019
Dual-mechanistic antibody-drug conjugate via site-specific selenocysteine/cysteine conjugation.
Antibody therapeutics. 2(4):71-78 [DOI] 10.1093/abt/tbz009. [PMID] 31930187.
2019
Engineering Dual Variable Domains for the Generation of Site-Specific Antibody-Drug Conjugates.
Methods in molecular biology (Clifton, N.J.). 2033:39-52 [DOI] 10.1007/978-1-4939-9654-4_4. [PMID] 31332746.
2019
Logic-Gated ROR1 Chimeric Antigen Receptor Expression Rescues T Cell-Mediated Toxicity to Normal Tissues and Enables Selective Tumor Targeting.
Cancer cell. 35(3):489-503.e8 [DOI] 10.1016/j.ccell.2019.02.003. [PMID] 30889382.
2019
Rabbit models of human diseases for diagnostics and therapeutics development.
Developmental and comparative immunology. 92:99-104 [DOI] 10.1016/j.dci.2018.10.003. [PMID] 30339876.
2019
ROR1-targeted delivery of miR-29b induces cell cycle arrest and therapeutic benefit in vivo in a CLL mouse model
Blood. 134(5):432-444 [DOI] 10.1182/blood.2018882290. [PMID] 31151986.
2019
Site-Selective Antibody Functionalization via Orthogonally Reactive Arginine and Lysine Residues.
Cell chemical biology. 26(9):1229-1239.e9 [DOI] 10.1016/j.chembiol.2019.05.010. [PMID] 31231031.
2019
Site-Specific Lysine Arylation as an Alternative Bioconjugation Strategy for Chemically Programmed Antibodies and Antibody–Drug Conjugates
Bioconjugate Chemistry. 30(11):2889-2896 [DOI] 10.1021/acs.bioconjchem.9b00609. [PMID] 31675216.
2019
Six-packed antibodies punch better.
Haematologica. 104(9):1696-1699 [DOI] 10.3324/haematol.2019.224196. [PMID] 31473607.
2018
A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era.
Blood. 132(5):521-532 [DOI] 10.1182/blood-2018-02-830992. [PMID] 29743179.
2018
A Sortase A Programmable Phage Display Format for Improved Panning of Fab Antibody Libraries.
Journal of molecular biology. 430(21):4387-4400 [DOI] 10.1016/j.jmb.2018.09.003. [PMID] 30213726.
2018
CAR T cells targeting αvβ3 integrin are effective against advanced cancer in preclinical models.
Advances in cell and gene therapy. 1(2) [DOI] 10.1002/acg2.11. [PMID] 30420973.
2018
Comparative Studies of the Biosynthetic Gene Clusters for Anthraquinone-Fused Enediynes Shedding Light into the Tailoring Steps of Tiancimycin Biosynthesis.
Organic letters. 20(18):5918-5921 [DOI] 10.1021/acs.orglett.8b02584. [PMID] 30212211.
2018
Potent and selective antitumor activity of a T cell-engaging bispecific antibody targeting a membrane-proximal epitope of ROR1.
Proceedings of the National Academy of Sciences of the United States of America. 115(24):E5467-E5476 [DOI] 10.1073/pnas.1719905115. [PMID] 29844189.
2018
Siglec-6 on Chronic Lymphocytic Leukemia Cells Is a Target for Post-Allogeneic Hematopoietic Stem Cell Transplantation Antibodies.
Cancer immunology research. 6(9):1008-1013 [DOI] 10.1158/2326-6066.CIR-18-0102. [PMID] 29980538.
2017
Chimeric rabbit/human Fab antibodies against the hepatitis Be-antigen and their potential applications in assays, characterization, and therapy.
The Journal of biological chemistry. 292(40):16760-16772 [DOI] 10.1074/jbc.M117.802272. [PMID] 28842495.
2017
From rabbit antibody repertoires to rabbit monoclonal antibodies.
Experimental & molecular medicine. 49(3) [DOI] 10.1038/emm.2017.23. [PMID] 28336958.
2017
Genome Mining of Micromonospora yangpuensis DSM 45577 as a Producer of an Anthraquinone-Fused Enediyne.
Organic letters. 19(22):6192-6195 [DOI] 10.1021/acs.orglett.7b03120. [PMID] 29086572.
2017
Harnessing a catalytic lysine residue for the one-step preparation of homogeneous antibody-drug conjugates.
Nature communications. 8(1) [DOI] 10.1038/s41467-017-01257-1. [PMID] 29062027.
2017
Mining Naïve Rabbit Antibody Repertoires by Phage Display for Monoclonal Antibodies of Therapeutic Utility.
Journal of molecular biology. 429(19):2954-2973 [DOI] 10.1016/j.jmb.2017.08.003. [PMID] 28818634.
2017
Stable and Potent Selenomab-Drug Conjugates.
Cell chemical biology. 24(4):433-442.e6 [DOI] 10.1016/j.chembiol.2017.02.012. [PMID] 28330604.
2017
Utilization of Selenocysteine for Site-Specific Antibody Conjugation.
Methods in molecular biology (Clifton, N.J.). 1575:145-164 [DOI] 10.1007/978-1-4939-6857-2_8. [PMID] 28255878.
2016
Assessment of reagents for selenocysteine conjugation and the stability of selenocysteine adducts.
Organic & biomolecular chemistry. 14(22):5141-7 [DOI] 10.1039/c6ob00775a. [PMID] 27184239.
2016
Chemically Programmed Bispecific Antibodies in Diabody Format.
The Journal of biological chemistry. 291(37):19661-73 [DOI] 10.1074/jbc.M116.745588. [PMID] 27445334.
2016
Engineered production of cancer targeting peptide (CTP)-containing C-1027 in Streptomyces globisporus and biological evaluation.
Bioorganic & medicinal chemistry. 24(17):3887-3892 [DOI] 10.1016/j.bmc.2016.04.017. [PMID] 27094150.
2016
Human Serum Albumin Domain I Fusion Protein for Antibody Conjugation.
Bioconjugate chemistry. 27(10):2271-2275 [PMID] 27666414.
2016
Strain Prioritization and Genome Mining for Enediyne Natural Products.
mBio. 7(6) [DOI] 10.1128/mBio.02104-16. [PMID] 27999165.
2016
Tagging the Untaggable: A Difluoroalkyl-Sulfinate Ketone-Based Reagent for Direct C-H Functionalization of Bioactive Heteroarenes.
Bioconjugate chemistry. 27(9):1965-71 [DOI] 10.1021/acs.bioconjchem.6b00382. [PMID] 27494153.
2016
Targeting Stereotyped B Cell Receptors from Chronic Lymphocytic Leukemia Patients with Synthetic Antigen Surrogates.
The Journal of biological chemistry. 291(14):7558-70 [DOI] 10.1074/jbc.M115.701656. [PMID] 26851280.
2015
Angucyclines and Angucyclinones from Streptomyces sp. CB01913 Featuring C-Ring Cleavage and Expansion.
Journal of natural products. 78(10):2471-80 [DOI] 10.1021/acs.jnatprod.5b00601. [PMID] 26335269.
2015
Chemical biology: How to minimalize antibodies.
Nature. 518(7537):38-9 [DOI] 10.1038/518038a. [PMID] 25652990.
2015
IGF1R- and ROR1-Specific CAR T Cells as a Potential Therapy for High Risk Sarcomas.
PloS one. 10(7) [DOI] 10.1371/journal.pone.0133152. [PMID] 26173023.
2015
Lipid-directed vinculin dimerization.
Biochemistry. 54(17):2758-68 [DOI] 10.1021/acs.biochem.5b00015. [PMID] 25880222.
2015
ROR1-targeted delivery of OSU-2S, a nonimmunosuppressive FTY720 derivative, exerts potent cytotoxicity in mantle-cell lymphoma in vitro and in vivo.
Experimental hematology. 43(9):770-4.e2 [DOI] 10.1016/j.exphem.2015.04.008. [PMID] 25937048.
2015
Safety of targeting ROR1 in primates with chimeric antigen receptor-modified T cells.
Cancer immunology research. 3(2):206-16 [DOI] 10.1158/2326-6066.CIR-14-0163. [PMID] 25355068.
2015
Site-Specific Dual Antibody Conjugation via Engineered Cysteine and Selenocysteine Residues.
Bioconjugate chemistry. 26(11):2243-8 [DOI] 10.1021/acs.bioconjchem.5b00244. [PMID] 26161903.
2015
The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity.
Cancer immunology research. 3(2):125-35 [DOI] 10.1158/2326-6066.CIR-14-0127. [PMID] 25212991.
2015
Tumor antigen ROR1 targeted drug delivery mediated selective leukemic but not normal B-cell cytotoxicity in chronic lymphocytic leukemia.
Leukemia. 29(2):346-55 [DOI] 10.1038/leu.2014.199. [PMID] 24947019.
2014
Antibody conjugation via one and two C-terminal selenocysteines.
Methods (San Diego, Calif.). 65(1):133-8 [DOI] 10.1016/j.ymeth.2013.05.023. [PMID] 23756202.
2014
Chemically programmed antibodies.
Trends in biotechnology. 32(4):186-97 [DOI] 10.1016/j.tibtech.2014.02.003. [PMID] 24630478.
2014
Harnessing the fcμ receptor for potent and selective cytotoxic therapy of chronic lymphocytic leukemia.
Cancer research. 74(24):7510-7520 [DOI] 10.1158/0008-5472.CAN-14-2030. [PMID] 25344228.
2014
Improving the serum stability of site-specific antibody conjugates with sulfone linkers.
Bioconjugate chemistry. 25(8):1402-7 [DOI] 10.1021/bc500276m. [PMID] 25099687.
2014
Recognition of antigen-specific B-cell receptors from chronic lymphocytic leukemia patients by synthetic antigen surrogates.
Chemistry & biology. 21(12):1670-9 [DOI] 10.1016/j.chembiol.2014.10.010. [PMID] 25467125.
2014
Selection of apoptotic cell specific human antibodies from adult bone marrow.
PloS one. 9(4) [DOI] 10.1371/journal.pone.0095999. [PMID] 24760047.
2013
Analysis of cell-cell contact mediated by Ig superfamily cell adhesion molecules.
Current protocols in cell biology. 61:9.5.1-9.5.85 [DOI] 10.1002/0471143030.cb0905s61. [PMID] 24510806.
2013
Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells.
Clinical cancer research : an official journal of the American Association for Cancer Research. 19(12):3153-64 [DOI] 10.1158/1078-0432.CCR-13-0330. [PMID] 23620405.
2012
Application of strain-promoted azide-alkyne cycloaddition and tetrazine ligation to targeted Fc-drug conjugates.
Bioconjugate chemistry. 23(10):2007-13 [DOI] 10.1021/bc300052u. [PMID] 22988967.
2012
Chemically programmed bispecific antibodies that recruit and activate T cells.
The Journal of biological chemistry. 287(34):28206-14 [DOI] 10.1074/jbc.M112.384594. [PMID] 22761439.
2012
Cloning, expression, and purification of monoclonal antibodies in scFv-Fc format.
Methods in molecular biology (Clifton, N.J.). 901:209-32 [DOI] 10.1007/978-1-61779-931-0_14. [PMID] 22723104.
2012
Generation of human Fab libraries for phage display.
Methods in molecular biology (Clifton, N.J.). 901:53-79 [DOI] 10.1007/978-1-61779-931-0_4. [PMID] 22723094.
2012
Restricted cell surface expression of receptor tyrosine kinase ROR1 in pediatric B-lineage acute lymphoblastic leukemia suggests targetability with therapeutic monoclonal antibodies.
PloS one. 7(12) [DOI] 10.1371/journal.pone.0052655. [PMID] 23285131.
2012
Selection of human Fab libraries by phage display.
Methods in molecular biology (Clifton, N.J.). 901:81-99 [DOI] 10.1007/978-1-61779-931-0_5. [PMID] 22723095.
2012
Targeting malignant B cells with an immunotoxin against ROR1.
mAbs. 4(3):349-61 [DOI] 10.4161/mabs.19870. [PMID] 22531447.
2011
A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease.
Blood. 117(20):5463-72 [DOI] 10.1182/blood-2010-12-324210. [PMID] 21385850.
2011
A novel high-affinity human monoclonal antibody to mesothelin.
International journal of cancer. 128(9):2020-30 [DOI] 10.1002/ijc.25557. [PMID] 20635390.
2011
Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation.
Blood. 117(2):542-52 [DOI] 10.1182/blood-2010-02-269514. [PMID] 20956803.
2011
DARTs take aim at BiTEs.
Blood. 117(17):4403-4 [DOI] 10.1182/blood-2011-02-337691. [PMID] 21527536.
2011
Generation of human Fab antibody libraries: PCR amplification and assembly of light- and heavy-chain coding sequences.
Cold Spring Harbor protocols. 2011(9) [DOI] 10.1101/pdb.prot065565. [PMID] 21880817.
2011
Generation of human scFv antibody libraries: PCR amplification and assembly of light- and heavy-chain coding sequences.
Cold Spring Harbor protocols. 2011(9) [DOI] 10.1101/pdb.prot065573. [PMID] 21880816.
2011
Therapeutic potential and challenges of targeting receptor tyrosine kinase ROR1 with monoclonal antibodies in B-cell malignancies.
PloS one. 6(6) [DOI] 10.1371/journal.pone.0021018. [PMID] 21698301.
2010
Generation and characterization of a chimeric rabbit/human Fab for co-crystallization of HIV-1 Rev.
Journal of molecular biology. 397(3):697-708 [DOI] 10.1016/j.jmb.2010.01.061. [PMID] 20138059.
2010
Implications of the HIV-1 Rev dimer structure at 3.2 A resolution for multimeric binding to the Rev response element.
Proceedings of the National Academy of Sciences of the United States of America. 107(13):5810-4 [DOI] 10.1073/pnas.0914946107. [PMID] 20231488.
2010
Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway.
Blood. 115(13):2619-29 [DOI] 10.1182/blood-2009-09-242438. [PMID] 19965642.
2010
Mining human antibody repertoires.
mAbs. 2(4):365-78 [PMID] 20505349.
2010
The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor.
Blood. 116(22):4532-41 [DOI] 10.1182/blood-2010-05-283309. [PMID] 20702778.
2010
The New Zealand black mouse as a model for the development and progression of chronic lymphocytic leukemia.
Cytometry. Part B, Clinical cytometry. 78 Suppl 1:S98-109 [DOI] 10.1002/cyto.b.20544. [PMID] 20839343.
2009
A human monoclonal antibody drug and target discovery platform for B-cell chronic lymphocytic leukemia based on allogeneic hematopoietic stem cell transplantation and phage display.
Blood. 114(20):4494-502 [DOI] 10.1182/blood-2009-05-222786. [PMID] 19667400.
2009
Contactin-2/TAG-1-directed autoimmunity is identified in multiple sclerosis patients and mediates gray matter pathology in animals.
Proceedings of the National Academy of Sciences of the United States of America. 106(20):8302-7 [DOI] 10.1073/pnas.0901496106. [PMID] 19416878.
2009
E. coli expression and purification of Fab antibody fragments.
Current protocols in protein science. Chapter 6 [DOI] 10.1002/0471140864.ps0610s55. [PMID] 19235139.
2009
Generation and selection of rabbit antibody libraries by phage display.
Methods in molecular biology (Clifton, N.J.). 525:101-28, xiv [DOI] 10.1007/978-1-59745-554-1_5. [PMID] 19252834.
2009
Molecular basis of the interactions of the Nogo-66 receptor and its homolog NgR2 with myelin-associated glycoprotein: development of NgROMNI-Fc, a novel antagonist of CNS myelin inhibition.
The Journal of neuroscience : the official journal of the Society for Neuroscience. 29(18):5768-83 [DOI] 10.1523/JNEUROSCI.4935-08.2009. [PMID] 19420245.
2009
Molecularly defined antibody conjugation through a selenocysteine interface.
Biochemistry. 48(50):12047-57 [DOI] 10.1021/bi901744t. [PMID] 19894757.
2009
Overview on concepts and applications of Fab antibody fragments.
Current protocols in protein science. Chapter 6 [DOI] 10.1002/0471140864.ps0609s55. [PMID] 19235140.
2008
An engineered selenocysteine defines a unique class of antibody derivatives.
Proceedings of the National Academy of Sciences of the United States of America. 105(34):12451-6 [DOI] 10.1073/pnas.0800800105. [PMID] 18719095.
2008
Application of a trifunctional reactive linker for the construction of antibody-drug hybrid conjugates.
Bioorganic & medicinal chemistry letters. 18(21):5785-8 [DOI] 10.1016/j.bmcl.2008.09.078. [PMID] 18922692.
2008
Generation, affinity maturation, and characterization of a human anti-human NKG2D monoclonal antibody with dual antagonistic and agonistic activity.
Journal of molecular biology. 384(5):1143-56 [DOI] 10.1016/j.jmb.2008.09.008. [PMID] 18809410.
2008
Mechanisms of CNS myelin inhibition: evidence for distinct and neuronal cell type specific receptor systems.
Restorative neurology and neuroscience. 26(2-3):97-115 [PMID] 18820405.
2008
Unique cell surface expression of receptor tyrosine kinase ROR1 in human B-cell chronic lymphocytic leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research. 14(2):396-404 [DOI] 10.1158/1078-0432.CCR-07-1823. [PMID] 18223214.
2007
Chimeric rabbit/human Fab and IgG specific for members of the Nogo-66 receptor family selected for species cross-reactivity with an improved phage display vector.
Journal of immunological methods. 318(1-2):75-87 [PMID] 17140598.
2007
Synthesis of the next-generation therapeutic antibodies that combine cell targeting and antibody-catalyzed prodrug activation.
Proceedings of the National Academy of Sciences of the United States of America. 104(13):5584-9 [PMID] 17372220.
2006
Small molecule drug activity in melanoma models may be dramatically enhanced with an antibody effector.
International journal of cancer. 119(5):1194-207 [PMID] 16570283.
2005
Neutralization of Burkholderia pseudomallei protease by Fabs generated through phage display.
Bioscience, biotechnology, and biochemistry. 69(12):2302-11 [PMID] 16377887.
2005
Phenotypic knockout of VEGF-R2 and Tie-2 with an intradiabody reduces tumor growth and angiogenesis in vivo.
Proceedings of the National Academy of Sciences of the United States of America. 102(23):8293-8 [PMID] 15928093.
2005
Targeting tumor angiogenesis with adenovirus-delivered anti-Tie-2 intrabody.
Cancer research. 65(3):972-81 [PMID] 15705898.
2005
The Nogo-66 receptor homolog NgR2 is a sialic acid-dependent receptor selective for myelin-associated glycoprotein.
The Journal of neuroscience : the official journal of the Society for Neuroscience. 25(4):808-22 [PMID] 15673660.
2004
Aldolase antibody activation of prodrugs of potent aldehyde-containing cytotoxics for selective chemotherapy.
Chemistry (Weinheim an der Bergstrasse, Germany). 10(21):5467-72 [PMID] 15378729.
2004
Chemical adaptor immunotherapy: design, synthesis, and evaluation of novel integrin-targeting devices.
Journal of medicinal chemistry. 47(23):5630-40 [PMID] 15509162.
2004
Human/mouse cross-reactive anti-VEGF receptor 2 recombinant antibodies selected from an immune b9 allotype rabbit antibody library.
Journal of immunological methods. 288(1-2):149-64 [PMID] 15183093.
2004
Integrin alphaIIbbeta3-specific synthetic human monoclonal antibodies and HCDR3 peptides that potently inhibit platelet aggregation.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 18(2):361-3 [PMID] 14688205.
2004
Isolation of human prostate cancer cell reactive antibodies using phage display technology.
Journal of immunological methods. 291(1-2):137-51 [PMID] 15345312.
2004
New chemical adaptor unit designed to release a drug from a tumor targeting device by enzymatic triggering.
Bioorganic & medicinal chemistry. 12(8):1853-8 [PMID] 15051054.
2004
Prodrugs of dynemicin analogs for selective chemotherapy mediated by an aldolase catalytic Ab.
Proceedings of the National Academy of Sciences of the United States of America. 101(9):3095-9 [PMID] 14981258.
2003
A chemical adaptor system designed to link a tumor-targeting device with a prodrug and an enzymatic trigger.
Angewandte Chemie (International ed. in English). 42(3):327-32 [PMID] 12548691.
2003
A humanized aldolase antibody for selective chemotherapy and adaptor immunotherapy.
Journal of molecular biology. 332(4):889-99 [PMID] 12972259.
2003
Chemically programmed monoclonal antibodies for cancer therapy: adaptor immunotherapy based on a covalent antibody catalyst.
Proceedings of the National Academy of Sciences of the United States of America. 100(9):5396-400 [PMID] 12702756.
2003
Intradiabodies, bispecific, tetravalent antibodies for the simultaneous functional knockout of two cell surface receptors.
The Journal of biological chemistry. 278(48):47812-9 [PMID] 12947084.
2003
Rabbit immune repertoires as sources for therapeutic monoclonal antibodies: the impact of kappa allotype-correlated variation in cysteine content on antibody libraries selected by phage display.
Journal of molecular biology. 325(2):325-35 [PMID] 12488098.
2002
Axonin-1/TAG-1 mediates cell-cell adhesion by a cis-assisted trans-interaction.
The Journal of biological chemistry. 277(6):4551-7 [PMID] 11733523.
2002
Integrin alpha(v)beta3 targeted therapy for Kaposi’s sarcoma with an in vitro evolved antibody.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 16(14):2000-2 [PMID] 12397091.
2001
Analysis of cell-cell contact mediated by Ig superfamily cell adhesion molecules.
Current protocols in cell biology. Chapter 9 [DOI] 10.1002/0471143030.cb0905s11. [PMID] 18228394.
2001
Antibody libraries in drug and target discovery.
Drug discovery today. 6(1):36-43 [PMID] 11165171.
2001
In vivo activity in a catalytic antibody-prodrug system: Antibody catalyzed etoposide prodrug activation for selective chemotherapy.
Proceedings of the National Academy of Sciences of the United States of America. 98(13):7528-33 [PMID] 11404472.
2001
The contactin-related protein FAR-2 defines purkinje cell clusters and labels subpopulations of climbing fibers in the developing cerebellum.
Molecular and cellular neurosciences. 18(1):91-107 [PMID] 11461156.
2000
A direct interaction of axonin-1 with NgCAM-related cell adhesion molecule (NrCAM) results in guidance, but not growth of commissural axons.
The Journal of cell biology. 149(4):951-68 [PMID] 10811834.
2000
Catalytic antibodies as magic bullets.
Chemistry (Weinheim an der Bergstrasse, Germany). 6(12):2091-5 [PMID] 10926212.
2000
From catalytic asymmetric synthesis to the transcriptional regulation of genes: in vivo and in vitro evolution of proteins.
Advances in protein chemistry. 55:317-66 [PMID] 11050938.
2000
Generation and characterization of a recombinant human CCR5-specific antibody. A phage display approach for rabbit antibody humanization.
The Journal of biological chemistry. 275(46):36073-8 [PMID] 10969070.
2000
Methods for the generation of chicken monoclonal antibody fragments by phage display.
Journal of immunological methods. 242(1-2):159-81 [PMID] 10986398.
2000
The rabbit antibody repertoire as a novel source for the generation of therapeutic human antibodies.
The Journal of biological chemistry. 275(18):13668-76 [PMID] 10788485.
2000
Using antibody catalysis to study the outcome of multiple evolutionary trials of a chemical task.
Proceedings of the National Academy of Sciences of the United States of America. 97(8):3878-83 [PMID] 10760259.
1999
Multiple event activation of a generic prodrug trigger by antibody catalysis.
Proceedings of the National Academy of Sciences of the United States of America. 96(12):6925-30 [PMID] 10359815.
1998
A phage display approach for rapid antibody humanization: designed combinatorial V gene libraries.
Proceedings of the National Academy of Sciences of the United States of America. 95(15):8910-5 [PMID] 9671778.
1998
Discrete clusters of axonin-1 and NgCAM at neuronal contact sites: facts and speculations on the regulation of axonal fasciculation.
Progress in brain research. 117:93-104 [PMID] 9932403.
1998
Neurite fasciculation mediated by complexes of axonin-1 and Ng cell adhesion molecule.
The Journal of cell biology. 143(6):1673-90 [PMID] 9852159.
1997
Phage display of combinatorial antibody libraries.
Current opinion in biotechnology. 8(4):503-8 [PMID] 9265732.
1996
Cell adhesion molecules NgCAM and axonin-1 form heterodimers in the neuronal membrane and cooperate in neurite outgrowth promotion.
The Journal of cell biology. 135(6 Pt 1):1593-607 [PMID] 8978825.
1996
Implications for the domain arrangement of axonin-1 derived from the mapping of its NgCAM binding site.
The EMBO journal. 15(9):2056-68 [PMID] 8641271.
1995
The gene of chicken axonin-1. Complete structure and analysis of the promoter.
European journal of biochemistry. 227(3):617-28 [PMID] 7867620.
1993
cDNA cloning, structural features, and eucaryotic expression of human TAG-1/axonin-1.
European journal of biochemistry. 211(1-2):329-39 [PMID] 8425542.
1993
Cell-cell adhesion by homophilic interaction of the neuronal recognition molecule axonin-1.
European journal of biochemistry. 215(1):133-41 [PMID] 8344273.
1992
The axonally secreted cell adhesion molecule, axonin-1. Primary structure, immunoglobulin-like and fibronectin-type-III-like domains and glycosyl-phosphatidylinositol anchorage.
European journal of biochemistry. 204(2):453-63 [PMID] 1311675.

Grants

Apr 2022 ACTIVE
Dual payload ADCs designed for mitigating cancer resistance (Hwang)
Role: Principal Investigator
Funding: AMER ASSO FOR CANCER RESEARCH
Apr 2022 ACTIVE
T-cell engaging bispecific antibodies designed for proteolytic activation in the tumor microenvironment
Role: Principal Investigator
Funding: NATL INST OF HLTH NCI
Apr 2022 ACTIVE
A Drug Delivery Strategy for Targeted Therapy of Chronic Lymphocytic Leukemia
Role: Principal Investigator
Funding: NATL INST OF HLTH NCI
Apr 2022 ACTIVE
Targeting delivery of siRNA-antibody conjugates
Role: Principal Investigator
Funding: ALNYLAM PHARMACEUTICALS
Apr 2022 ACTIVE
Novel Enediyne-Based Antibody-Drug Conjugates for Cancers
Role: Principal Investigator
Funding: NATL INST OF HLTH NCI
Apr 2022 – Sep 2022
NSRA Training Core
Role: Principal Investigator
Funding: SCRIPPS RESEARCH INST via NATL INST OF HLTH NCATS

Education

Ph.D. in Biochemistry
1995 · University of Zurich (Switzerland)
Master's of Science in Biochemistry
1991 · University of Zurich (Switzerland)
Bachelor's of Science in Biochemistry
1988 · University of Bayreuth (Germany)

Contact Details

Phones:
Business:
(561) 228-2053
Emails:
Business:
c.rader@ufl.edu
Addresses:
Business Mailing:
Location C231
130 SCRIPPS WAY BLDG 2C1
JUPITER FL 33458